Both of these can make local
rates shift over time, and savvy consumers always look at how they may be able to re-negotiate their Santa Monica insurance policies.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated
shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products
over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange
rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from
time to
time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
The team used a new
rating system to document these interactions, allowing them to determine the rank orders of male and female chimpanzees and watch how they
shifted over time.
It is
time for the evaluation debate
over school choice to begin
shifting its focus to real world outcomes, like high school graduation and college attendance
rates.
Trended credit data reflects patterns in borrower behavior, such as
shifts in the number of balance decreases
over time, or increases in the
rate of a borrower's utilization — the portion of the individual's credit limit represented by their outstanding balances.
Remember, while these numbers slowly
shift over time, the total you owe for principal and interest doesn't change on a fixed -
rate loan.
But what of the
shift in opinions regarding the level of the Fed Funds
rate over time?
By adjusting the nominal interest
rate to compensate for the effects of inflation, you are identifying the
shift in purchasing power of a given level of capital constant
over time.
His tactics
shifted over time, but he was always looking to compound free cash flows at the best possible
rate.
But because money market
rates change
over time in response to economic
shifts and changes at banks, it's critical to not simply glance at the
rate you see on the bank's window or website and assume that that's all there is to know.
-- What's the mean avg growth in global CO2 and CO2e last year and
over the prior ~ 5 years — What's the current global surface temperature anomaly in the last year and in prior ~ 5 years — project that mean avg growth in CO2 / CO2e ppm increasing at the same
rate for another decade, and then to 2050 and to 2075 (or some other set of years)-- then using the best available latest GCM / s (pick and stick) for each year or quarter update and calculate the «likely» global surface temperature anomaly into the out years — all things being equal and not assuming any «fictional» scenarios in any RCPs or Paris accord of some massive
shift in projected FF / Cement use until such
times as they are a reality and actually operating and actually seen slowing CO2 ppm growth.
This analysis is probably floored, and the economics probably a little better because power prices will rise
over time and batteries partially cycle from moment to moment and so can actually
shift more power but this is of little economic benefit when net metering is available (giving near retail
rates to exported power) and so the fact remains batteries are still uneconomic by a factor of 300 % even with the SGIP.
These portions should increase
over time as fixed -
rate premiums increase, since they will lose the cross-subsidy from lower - annual - mileage motorists, eventually causing the market to
shift to PAYD pricing, although this would probably take a decade or so.